Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

inducible CD4+CD25+ regulatory T cells

Inducible regulatory T-lymphocytes that express CD4, CD25 (the alpha chain of the interleukin 2 receptor) and forkhead box P3 (FOXP3), with potential immunomodulating activity. Inducible CD4+CD25+ T regulatory cells (iTregs) are a subset of CD4+ T lymphocytes that are induced from CD25- precursors in peripheral lymphoid organs with interleukin-2 and transforming growth factor-beta. These regulatory T cells are essential in maintaining immunologic homeostasis. They may also prevent autoimmunity by suppressing self-reactive T cells, and may induce tolerance to allogeneic organ transplants such as in hematopoietic stem cell transplants.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	iTregs

inducible CD4+CD25+ regulatory T cells

Search NCI's Drug Dictionary